GlassScriptPhysician profile
Meridith A Mcguffey
NPI 1427455310
$4,233.46
in general payments reported to CMS, 2019-2025
23 companies · $1,196 in 2025
The $1,196 reported for 2025 was more than what 86% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $847 · 2022: $734 · 2023: $824 · 2024: $633 · 2025: $1,196.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,570 · Education: $82.95.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,569.63 |
| Education | $82.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sun Pharmaceutical Industries INC. | $579.03 | 2021-2025 | Ilumya, Winlevi, Absorica Ld |
| Abbvie INC. | $541.89 | 2021-2025 | |
| Genzyme Corporation | $459.38 | 2021-2025 | |
| Pfizer INC. | $302.08 | 2021-2025 | |
| Incyte Corporation | $292.91 | 2021-2025 | Opzelura |
| Novartis Pharmaceuticals Corporation | $264.47 | 2021-2023 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $263.44 | 2021-2025 | Siliq, Jublia, Arazlo |
| Regeneron Healthcare Solutions, INC. | $225.00 | 2022-2024 | Libtayo, Dupixent |
| Amgen INC. | $208.37 | 2021-2025 | Otezla, Otezla |
| Lilly USA, LLC | $153.53 | 2021-2022 | |
| Journey Medical Corporation | $117.99 | 2022-2025 | |
| Mayne Pharma Commercial LLC | $110.59 | 2021-2025 | |
| Leo Pharma INC. | $97.85 | 2025 | Adbry, Anzupgo |
| Janssen Biotech, INC. | $82.85 | 2021-2025 | Tremfya |
| E.R. Squibb & Sons, L.L.C. | $79.33 | 2023-2024 | Sotyktu |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ucb, INC. | $75.85 | 2024-2025 | Bimzelx |
| Sanofi-Aventis U.S. LLC | $72.00 | 2021 | |
| Galderma Laboratories, L.P. | $65.80 | 2024-2025 | Aklief, Nemluvio |
| Almirall LLC | $64.70 | 2021-2024 | Klisyri |
| Arcutis Biotherapeutics, INC. | $59.46 | 2024-2025 | Zoryve |
| Botanix Sb INC | $52.62 | 2025 | Sofdra |
| Vyne Pharmaceuticals INC. | $32.84 | 2021 | |
| Dermira, INC. | $31.48 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Meridith Mcguffey listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.